Yaupon names Steve Tullman chairman and CEO
This article was originally published in Scrip
Yaupon Therapeutics, a privately held speciality pharma company developing small-molecule pharmaceuticals licensed from academic institutions, has appointed Steve Tullman chairman and CEO. Mr Tullman was previously co-founder and president of Ception Therapeutics, which was acquired by Cephalon in 2010. He currently serves as chairman of Vicept Therapeutics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.